PetVivo Holdings, Inc. (PETV) corporate presentation covering the Kush(tm) canine and equine joint injection osteoarthritis treatment and how it stacks up against competitors. Also covered are Kush(tm) treatment market estimates, the PETV product pipeline and IP portfolio. The appendixes cover additional products and the technology and manufacturing processes and potential, human therapeutics products and market estimates including SynovoLife, CosmetaLife, DiscLife, UroLife and the VasoShunt cardiovascular products.
17. Proven!Products!E!Validated!Mfg.!!
Pet!Market!Launch!Ready!
• Demonstrated!Human!Safety!&!Efficacy!
o Classified!as!a!Medical!Device!by!the!FDA!!
o Pivotal!FDA!Human!Trial!Successfully!Completed!!
o Ten!Years!of!Safety!&!Efficacy!in!Many!Species!
• Validated!Manufacturing!!
o Manufacturing!FDA!Validated!For!Human!Trial!!
o SingleEUse!Inline!MFG!Processes!
o Very!Scalable!Manufacturing!!
o Low!CAPEX!Infrastructure!!
o Room!Temp!Stable!Beyond!24!Months!
• Commercial!Ready!in!Pet/Vet!Market!
o ParNcles!Defined!as!a!Medical!Device!!
o No!FDA!Clearance!Required!for!Vet!Devices!
o Significant!Margins!!
!
!
!
CloseEup!of!
syringe!needle!
point!
ParNcles!
25. Bener!Implant!Material:!Why?!!
• Isolated!Purified!Components!
o Source!Tissues!Purified!to!Soluble!Component!Form!!
o Memory!of!Source!Tissue!Type!Removed!!
• Precludes!Wrong!Tissue!Response!e.g.,!Cadaveric!Tissue!!
o No!Inflammatory!or!Foreign!Body!Response!!
• Comprised!of!Collagen,!ElasNn!&!Heparin!
o Same!Components!As!Natural!Extracellular!Matrix!
• Components!SelfEAssemble!=!BiocoacervaNon!
o Forms!Insoluble!Matrix!–!Slippery,!Wet,!Permeable,!Durable!&!Resilient!
o Mimics!Natural!Precursor!Scaffold!in!ComposiNon,!Structure!&!HydraNon!
o Promotes!NeovascularizaNon!&!is!NonEClo~ng!
o Facilitates!Cellular!IntegraNon!&!RegeneraNon!of!FuncNonal!Tissue!
• Flexible!&!Adjustable!Biomaterial!Plavorm!!
o Modifying!ComposiNon!&!Components!Adjusts!Material!CharacterisNcs!
!
33. !Cardiovascular!Devices!&!Markets!
• VasoShunt!–!Arteriovenous!(AV)!Shunt!
o Annually!≈250,000!US!Dialysis!PaNents!Require!Vascular!Access!(US!Renal!Data!System)!
o Over!50%!of!NaNve!&!ePTFE!Shunts!Fail!Within!1!year(1)!
• VasoShunt!–!Temporary!Vascular!Shunt!for!Limb!Salvage!
o Treatment!of!Vascular!Injuries!in!Military!Theatre!&!Trauma!Se~ngs!
o No!Current!Temporary!Shunts!Have!NonEClo~ng!Feature!of!VasoShunt!
• Peripheral!Vascular!Gra{!!
o WW!Market!Growing!From!$6.6B!in!2014!to!$8.4B!in!2018!–!CAGR!of!6.3%!(BCC!Research)!
o No!Peripheral!Vascular!Gra{s!with!NonEclo~ng!Features!of!VasoGra{!Available!!
• Coronary!Artery!Bypass!Gra{!
o 400,000!CABG!Procedures!Annually!In!US!(American!Heart!AssociaNon)!
o No!OffETheEShelf!Small!Diameter!Gra{s!Currently!Available!
!
(1)Akoh!JA.!ProstheNc!AV!!Gra{s!for!!Hemodialysis.!J!Vasc!Access.!2009!JulESep;10(3):137E47.!Review.!PubMed!PMID:!19670164.!
34. VasoGra{!&!VasoShunt!–!Biomaterial!Conduit!!!!
NonEClo~ng!ArNficial!Blood!Vessel
• $5.7!M!in!NIH!Grant!Funding!
• Successful!180EDay!Swine!Studies!
• Successful!Pilot!ProducNon!
• Any!Type!of!Vascular!Gra{!or!Shunt!!
• Bener!Than!Gold!Standard!ePTFE!Gra{s!
• NonEClo~ng!ProperNes!
o Devices!&!Device!CoaNngs!
o Improve!Any!Blood!ContacNng!Device!
o Stents,!Gra{s,!Catheters,!etc.!
o Allows!Small!Diameter!Gra{s!
• Inherent!Drug!Delivery!Capability!
!
CaroNd!
artery!
VasoShunt!
2!wk!implantaNon!(ovine)!
VasoShunt!
End!to!side!anastomosis!with!12!cm!long!VasoE!!!
Gra{!shunNng!caroNd!to!jugular!in!sheep!(n=6)!